Smith & Nephew (SN) Lowered to Neutral at BNP Paribas

Smith & Nephew (LON:SN) was downgraded by research analysts at BNP Paribas to a “neutral” rating in a research note issued to investors on Friday. They currently have a GBX 1,525 ($19.93) price objective on the stock, up from their prior price objective of GBX 1,475 ($19.27). BNP Paribas’ target price indicates a potential downside of 0.03% from the stock’s current price.

Other research analysts have also recently issued research reports about the stock. Credit Suisse Group boosted their price objective on shares of Smith & Nephew from GBX 1,330 ($17.38) to GBX 1,390 ($18.16) and gave the company a “neutral” rating in a report on Friday. Deutsche Bank upgraded shares of Smith & Nephew to a “hold” rating and boosted their price objective for the company from GBX 1,200 ($15.68) to GBX 1,350 ($17.64) in a report on Monday, December 10th. UBS Group boosted their price objective on shares of Smith & Nephew from GBX 1,340 ($17.51) to GBX 1,390 ($18.16) and gave the company a “neutral” rating in a report on Monday, January 28th. JPMorgan Chase & Co. cut shares of Smith & Nephew to a “neutral” rating and set a GBX 1,477 ($19.30) price objective for the company. in a report on Wednesday, January 2nd. Finally, HSBC cut shares of Smith & Nephew to a “hold” rating and boosted their price objective for the company from GBX 1,400 ($18.29) to GBX 1,500 ($19.60) in a report on Tuesday, October 16th. Eight analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of GBX 1,479.40 ($19.33).

SN opened at GBX 1,525.50 ($19.93) on Friday. Smith & Nephew has a fifty-two week low of GBX 1,173 ($15.33) and a fifty-two week high of GBX 1,442 ($18.84).

About Smith & Nephew

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

Featured Story: How Do Tariffs Affect Trade Balances?

Analyst Recommendations for Smith & Nephew (LON:SN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply